Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.

[1]  M. Dimopoulos,et al.  The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis , 2008, Leukemia.

[2]  D. Esseltine,et al.  Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma , 2008, British journal of haematology.

[3]  N. Munshi,et al.  Bortezomib in the front-line treatment of multiple myeloma , 2008, Expert Review of Anticancer Therapy.

[4]  Zhi-wei Li,et al.  NF-κB in the pathogenesis and treatment of multiple myeloma , 2008, Current opinion in hematology.

[5]  W. Jędrzejczak,et al.  Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Esseltine,et al.  Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up , 2008, British journal of haematology.

[7]  M. Boccadoro,et al.  Thalidomide for treatment of multiple myeloma: 10 years later. , 2008, Blood.

[8]  B. Cheson,et al.  Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[10]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[11]  R. Foà,et al.  Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Fink,et al.  Hemostatic dysfunction in paraproteinemias and amyloidosis. , 2007, Seminars in thrombosis and hemostasis.

[13]  G. Morgan,et al.  Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.

[14]  J. Berenson,et al.  A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma , 2007, Clinical Cancer Research.

[15]  T. Choueiri,et al.  Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Moss,et al.  Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study , 2006, British journal of haematology.

[17]  P. Richardson,et al.  Lenalidomide in multiple myeloma , 2006, Expert review of anticancer therapy.

[18]  B. Barlogie,et al.  Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism , 2006, British journal of haematology.

[19]  Gordan Srkalovic,et al.  Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. , 2006, Mayo Clinic proceedings.

[20]  John Crowley,et al.  Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. , 2006, Blood.

[21]  V. Seshadri,et al.  Efficacy of prophylactic warfarin for prevention of thalidomide‐related deep venous thrombosis , 2006, American journal of hematology.

[22]  J. Zeldis,et al.  Lenalidomide and venous thrombosis in multiple myeloma. , 2006, The New England journal of medicine.

[23]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[24]  John Crowley,et al.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.

[25]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Bosi,et al.  Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients , 2006, Leukemia & lymphoma.

[27]  S. Andresen,et al.  Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients , 2006, Medical oncology.

[28]  J. Moake,et al.  Enhanced platelet adhesion and aggregation by endothelial cell-derived unusually large multimers of von Willebrand factor. , 2006, Biorheology.

[29]  M. Dimopoulos,et al.  Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. , 2006, Haematologica.

[30]  Robert A Kyle,et al.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.

[31]  Liang Li,et al.  The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. , 2005, Mayo Clinic proceedings.

[32]  S. Jagannath,et al.  A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. , 2005 .

[33]  V. Ganju,et al.  A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma , 2005, Clinical Cancer Research.

[34]  K. Dellagi,et al.  First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma , 2005, Bone Marrow Transplantation.

[35]  Michael L. Wang,et al.  Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma , 2005, American journal of hematology.

[36]  S. Jones,et al.  Relative Thromboembolic Risks Associated with COX-2 Inhibitors , 2005, The Annals of pharmacotherapy.

[37]  L. Heilbrun,et al.  Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature , 2005, Bone Marrow Transplantation.

[38]  F. Rosendaal,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[39]  S. Seeber,et al.  Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma , 2005, European journal of haematology.

[40]  M. Borad,et al.  Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma , 2005, Leukemia.

[41]  E. Vellenga,et al.  Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study , 2005, Annals of Hematology.

[42]  H. Goldschmidt,et al.  Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy , 2004, Leukemia.

[43]  B. Pégourié,et al.  Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients. , 2004 .

[44]  B. Barlogie,et al.  Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT). , 2004 .

[45]  P. Vos,et al.  The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  J. Berenson,et al.  A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. , 2004, Clinical lymphoma.

[47]  Bart Barlogie,et al.  Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation , 2004, British journal of haematology.

[48]  Gordan Srkalovic,et al.  Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease , 2004, Cancer.

[49]  M. Varettoni,et al.  Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone , 2004, Annals of Hematology.

[50]  D. Hoppensteadt,et al.  Erythropoietin-Induced Thrombosis as a Result of Increased Inflammation and Thrombin Activatable Fibrinolytic Inhibitor , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[51]  M. Tallman,et al.  Intravascular clotting activation and bleeding in patients with hematologic malignancies. , 2004, Reviews in clinical and experimental hematology.

[52]  M. Dimopoulos,et al.  Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. , 2004, The hematology journal : the official journal of the European Haematology Association.

[53]  F. Ravandi,et al.  Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma , 2004, British journal of haematology.

[54]  J. Miguel,et al.  The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma , 2004, Leukemia.

[55]  G. Kaushal,et al.  Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphology , 2004 .

[56]  Sante Tura,et al.  First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. , 2004, Haematologica.

[57]  T. Barbui,et al.  Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. , 2004, Haematologica.

[58]  K. Zervas,et al.  Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  J. Cavenagh,et al.  An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. , 2003, Leukemia research.

[60]  C. Eby,et al.  Hemostatic complications associated with paraproteinemias. , 2003, Current hematology reports.

[61]  C. Straka,et al.  Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma , 2003, British journal of haematology.

[62]  L. Mileshkin,et al.  Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. , 2003, Blood.

[63]  A. Turpie,et al.  Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[64]  B. Barlogie,et al.  The blood coagulation mechanism in multiple myeloma. , 2003, Seminars in thrombosis and hemostasis.

[65]  A. Anagnostopoulos,et al.  Thalidomide and dexamethasone for resistant multiple myeloma , 2003, British journal of haematology.

[66]  Santhosh K. P. Kumar,et al.  Thalidomide as initial therapy for early-stage myeloma , 2003, Leukemia.

[67]  D. Weber,et al.  Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Robert A Kyle,et al.  Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  G. Lip,et al.  The hypercoagulable state of malignancy: pathogenesis and current debate. , 2002, Neoplasia.

[70]  H. Goldschmidt,et al.  Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[72]  M. Díaz-Ricart,et al.  Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro , 2002, Thrombosis and Haemostasis.

[73]  B. Barlogie,et al.  Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. , 2002, Blood.

[74]  Hannes Kaufmann,et al.  Thromboembolic events during treatment with thalidomide. , 2002, Blood.

[75]  B. Boutouyrie,et al.  Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. , 2002, Thrombosis research.

[76]  H. Goldschmidt,et al.  Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. , 2001, Blood.

[77]  M. Samama,et al.  The Thrombophilic State in Cancer Patients , 2001, Acta Haematologica.

[78]  A. Falanga,et al.  Pathogenetic Mechanisms of Thrombosis in Malignancy , 2001, Acta Haematologica.

[79]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[80]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[81]  S. Rajkumar,et al.  Deep venous thrombosis and thalidomide therapy for multiple myeloma. , 2001, The New England journal of medicine.

[82]  R. Fonseca,et al.  Thalidomide for previously untreated indolent or smoldering multiple myeloma , 2001, Leukemia.

[83]  R. Fonseca,et al.  Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[85]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[86]  P. Thiagarajan,et al.  Light‐chain paraproteins with lupus anticoagulant activity , 1999, American journal of hematology.

[87]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[88]  C. Esmon.  Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. , 1994, Bailliere's clinical haematology.

[89]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[90]  D. Gabriel,et al.  The influence of immunoglobulin (IgG) on the assembly of fibrin gels. , 1983, The Journal of laboratory and clinical medicine.

[91]  D. Catovsky,et al.  Thromboembolic Complications in Myelomatosis , 1970, British medical journal.